Floatz logo

Ningmitai

Chronic Prostatitis

Xintian PharmaceuticalPhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Chronic Prostatitis cohort.

View all 20

Same molecule, other indications

Ningmitai is also rated in:

Chronic Prostatitis With Chronic Pelvic Pain SyndromeDormant
BB
Indicative ·
69 / 100
View asset →
erectile dysfunctionDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →